Patients and Methods
Our study population included 160 211 men aged ≥40 years with at least one visit to a primary care clinic in any of the study years in a large, integrated health system. We conducted a retrospective cohort study using electronic medical record data from January 2007 to December 2014. Yearly rates of screening PSA testing by primary care providers (PCPs), rates of re-screening, and rates of prostate biopsies were assessed.
Results
Annual PSA-screening testing declined from 2007 to 2014 in all age groups, as did biennial and quadrennial screening. Yearly rates declined for men aged ≥70 years, from 22.8% to 8.9%; ages 50-69 years, from 39.2% to 20%; and ages 40-49 years, from 11% to 4.6%. Overall rates were lower for African-American (A-A) men vs non-A-A men; for men with a family history of prostate cancer, rates were similar or slightly higher than for those without a family history. PCP variation associated with ordering of PSA testing did not substantially change after the USPSTF recommendations. While the number of men screened and rates of follow-up prostate cancer screening declined in 2011-2014 compared to 2007-2010, similar re-screening rates were noted for men aged 45-75 years with initial PSA levels of <1 ng/mL or 1-3 ng/mL in both the earlier and later cohorts. For men aged >75 years with initial PSA levels of <3 ng/mL screened in both cohorts, follow-up screening rates were similar. Rates of prostate biopsy declined for men aged ≥70 years in 2014 compared to 2007. For men who had PSA screening, rates of first prostate biopsy increased in later years for A-A men and men with a family history of prostate cancer.
Introduction
Prostate cancer is common and may affect up to 14% of men in their lifetime [1] . Established risk factors for prostate cancer include older age, African-American (A-A) race, and a family history of prostate cancer. Compared to White men, A-A men in the USA have a 58% greater incidence and 144% greater risk of mortality related to prostate cancer [2] . Regarding family history, the relative risk of developing prostate cancer is 2.48 with a first-degree relative with prostate cancer, and even higher if the affected family member is a brother [2] .
About 80% of prostate cancers are localised with 5-year relative survival rates of 100% [1] and there has been conflicting evidence for the mortality benefit of screening with the PSA test [3, 4] . Thus the potential for over diagnosis and harms of treatment including effects on sexual function and urinary symptoms [5, 6] , even in men with known risk factors for prostate cancer, have led to evolving practice guidelines for prostate cancer screening over the past several years [7] [8] [9] [10] . In 2008, the United States Preventive Services Task Force (USPSTF) recommended against prostate cancer screening with the PSA test in men aged >75 years [7] and in 2012, extended this recommendation to men of any age; they did not recommend a risk-based screening approach [8] . In contrast, both the American College of Physicians (ACP) and AUA recommend a shared decision-making approach to screening of men aged <70 years with consideration of individual risks [9, 10] . The recent National Comprehensive Cancer Network (NCCN) Guidelines [11] suggest once the screening decision is made, follow-up screening should occur based upon PSA level. The differing recommendations for prostate cancer screening have created confusion for primary care providers (PCPs). Previous studies reported that these guidelines reduced PSA screening rates in men >75 years [12] [13] [14] [15] , although studies of self-reported PSA testing [16] [17] [18] and PCP PSA ordering have not [19] .
Variation in PCP ordering of PSA testing in men aged >75 years [20] and with limited life-expectancy [21] has been described. Screening test ordering behaviour may be associated with physician characteristics as well as beliefs [22, 23] . However, it is not known to what extent changes in prostate cancer screening patterns since the initial USPSTF recommendations in 2008 are related to guideline recommendations, patient risk factors such as age, A-A race or family history of prostate cancer, or PCP factors in routine primary care practice. We also do not understand current primary care practice patterns for follow-up screening. Thus we sought to: (i) assess trends in prostate cancer screening and re-screening rates in primary care practices in a large, integrated health system from 2007 to 2014, as related to age and risk factors for prostate cancer and changing guideline recommendations for screening; (ii) assess PCP variation in PSA testing; and (iii) assess rates of prostate biopsies during this period.
Patients and Methods
The Cleveland Clinic Health System (CCHS) provides outpatient primary care at 41 practices in diverse settings across Northeast Ohio, USA. We conducted a retrospective cohort study using electronic medical record data (Epic system) from January 2007 to December 2014. We identified all men aged ≥40 years who had at least one visit in an Internal Medicine (IM) or Family Medicine (FM) clinic in the CCHS in any of the study years. We excluded men with a diagnosis of prostate cancer [International Classification of Diseases, ninth revision (ICD-9) codes 185, 233.4, 236.5 or V10.46] prior to the first PSA test in each study year. We obtained all visit dates for IM and FM visits, all Urology department visits in the CCHS, and all PSA test results in the study years. We used the reported PSA values in the structured laboratory results field in the electronic medical record data. To further focus our analysis on PSA tests performed for screening in primary care practices, we then excluded any PSA test result for a patient if he had a visit with a CCHS Urology department before the PSA test date each year and also excluded PSA tests ordered as 'PSA diagnostic' and 'PSA free', as well as any PSA test results associated with a specific symptom diagnosis code i.e., an ICD-9 code other than a V code.
For our analysis of PCP variation in PSA testing, we used the group of IM or FM visit providers and assigned the PCP for each patient as the PCP that the patient had seen most in the year the PSA blood test was drawn or the year prior. When there were an equal number of visits to more than one PCP, the PCP was assigned through random selection. For each year, we were able to choose the PCP based upon greatest visit frequency 87% of the time, with the remaining PCPs assigned through random selection of PCPs with whom the patient had an equal number of visits. We limited all of our analyses to PCPs who had at least 100 unique patient visits per year in our dataset.
Mixed-effects logistic regression models were used to adjust patient characteristics to analyse PCP variation adjusted for patient age and race (A-A vs non-A-A).
We calculated rates of PSA screening tests in each study year stratified by the following age groups: ≥70, 50-69, and 40-49 years, based upon the recent ACP and AUA guideline recommendations against screening men aged ≥70 years, and to use an individualised approach for younger men, starting at the age of 50 (ACP) or 55 years (AUA) or earlier based upon risk factors. We then calculated rates of screening in men known to have a higher risk of prostate cancer and compared rates of screening in A-A men vs non-A-A men and men with a family history of prostate cancer vs men without a family history in these age groups using the chisquared test.
To determine if screening rates in high-risk groups were related to interaction with the healthcare system, we calculated and compared 'ever-screened' rates for A-A vs non-A-A men and for men with a family history of prostate cancer vs men without a family history, then calculated and compared number of visits per year with PCPs (either IM or FM), as well as number of visits per year with a urology provider in these groups.
To assess frequency of follow-up PSA screening patterns for men who were screened in relation to timing of the USPSTF guidelines, we then created two cohorts of patients , to correspond with the timing of the later USPSTF guidelines against PSA testing in any age group, and these men remained in the cohort in 2013-2014. Re-screening rates were assessed in this cohort by age and PSA level, to correspond with the recent NCCN guideline recommendations. We examined re-screening rates for men aged 45-75 years with an initial PSA level of <1 and 1-3 ng/mL, and also assessed re-screening rates for men aged >75 years with a PSA level of <3 ng/mL. We did not assess re-screening for men with PSA levels of >3 ng/mL, as our dataset was created to assess PCP prostate cancer screening patterns and excluded men who had a Urology department visit prior to the PSA test each year. Our laboratory upper limit of normal was a PSA level of 4 ng/mL at the beginning of the study and was reduced to 2.59 ng/mL in the later years of the study, thus by design our dataset may have excluded most men with elevated PSA levels of >3 ng/mL who would have been referred to a urologist for an abnormal PSA level.
In addition, to determine if screening rates were related to a shift to increased screening intervals, we then analysed biennial, as well as quadrennial testing for men screened in 2008 vs men first screened in 2010.
We calculated prostate biopsy rates by identifying prostate biopsies using procedure codes for prostate biopsy and resultant pathology reports in the electronic medical records were also searched for 'prostate'. Rates of prostate biopsy were determined for each year of the study by age group, A-A race, and family history of prostate cancer. These annual analyses were completed using all men aged ≥40 years with a PCP visit each year as the denominator and using all prostate biopsy data. A second annual analysis was performed assessing rate of first prostate biopsy after a PSA test each year with only those men who had a screening PSA test in the denominator.
All analyses were conducted using R-Studio Version 3.0.2 (Boston, MA, USA).
Results
Our study population included 160 211 men aged ≥40 years from January 2007 to December 2014. The rates of PSA screening tests declined from 2007 to 2014 in all age groups (Fig. 1) . For men aged ≥70 years, rates declined from 22.8% to 8.9%, while for men aged 40-49 years, rates declined from 11.0% to 4.6%. In men aged 50-69 years, screening rates declined from 39.2% to 20.0%. For A-A men, the rates of screening were higher than for non-A-A men in the 40-49 years age group (Fig. 2 ) but lower than non-A-A men in the 50-69 years age group (Fig. 3) . For men with a family history of prostate cancer, the screening rates were also higher than for those without a family history in the 40-49 years age group (Fig. 4) , but not consistently higher in men aged 50-69 years (Fig. 5) . Throughout the study period, rates of PSA screening remained similar or lower for A-A men than for non-A-A men, decreasing from 27% in 2007 to 11% in 2014 (Table S1 ). For men with a family history of prostate cancer, rates of PSA screening remained similar or slightly higher throughout the study period.
We also found that A-A men were 'ever-screened' for prostate cancer less often (0.63) urology visits (P < 0.001). For men with a family history of prostate cancer, the 'ever-screened' rate was higher than for men without a family history, with 34.6% (1 107/3 202) of men with a family history of prostate cancer screened in any of the study years vs 28.4% (44 600/157 009) of men without a family history of prostate cancer (P < 0.001). The mean (SD) number of follow-up PCP visits per year was not significantly more for men with a family history of prostate cancer than for those without a family history, at 1.95(1.46) vs 1.91 (1.60), respectively (P = 0.41), but the mean (SD) number of follow-up urology visits per year was greater, at 0.35 (0.92) vs 0.21 (0.65), respectively (P < 0.001).
Provider variation in ordering PSA screening tests remained large throughout our study period, ranging from 0% to a maximum of 51.9-62.2% depending on the year (Fig. 6 , Table S2 ). The provider variation rates adjusted by patient age and race (A-A vs non-A-A) showed a similar pattern of variation (Table S3) .
Analysis of the two longitudinal cohorts between 2007 and 2014 showed that while the number of men screened declined in the 2011-2014 cohort compared to the 2007-2010 cohort, and rates of follow-up prostate cancer screening also declined, similar follow-up screening rates were noted for men aged 45-75 years with initial PSA levels of <1 or 1-3 ng/mL, in both the earlier and later cohorts. Men with higher PSA levels were not more likely to be re-screened in either cohort, and men aged >75 years with PSA levels of <3 ng/mL were rescreened at the same rate in both 2009-2010 and 2013-2014 (Tables 1 and 2 ).
For men screened in 2008, while the overall annual screening rates and by age group were lower in 2012, over half of men were re-screened once within a 4-year period, with lower rates for men aged >75 years. However, only 24% of men screened in 2008 were re-screened more than twice in 4 years (Table 3) . For the much lower number of men first screened in 2010, 43% were re-screened within 4 years, with only 20% re-screened more than twice in 4 years. For men aged >75 years the screening and re-screening rates were much lower in this later period (Table 4) .
Using all men aged ≥40 years with a PCP visit each year as the denominator, overall yearly rates of prostate biopsy were similar between 2007 and 2014. However, for men in the ≥70 years age group, biopsy rates decreased in 2014 compared to 2007, while for men with a family history of prostate cancer, biopsy rates increased in 2014 compared to 2007 (Table 5 ). When analysing rates of first prostate biopsy after a PSA screening test, with all men who had a PSA test included in the denominator, the rates of prostate biopsies were increased for A-A men and men with a family history of prostate cancer in 2014 compared to 2007 (Table 6 ).
Discussion
In the present retrospective study of primary care practices in a single health system, we found that yearly rates of prostate cancer screening with the PSA test declined in all age groups after the initial USPSTF recommendation in 2008 against screening men aged >75 years. Biennial and quadrennial screening rates were also lower for men first screened in 2010 compared to those men screened in 2008. Our present findings support a recent report that PSA testing was reduced among primary care physicians after 2010 [24] , but differs from a report of recent trends in primary care PSA ordering patterns [19] . Interestingly, in all age groups, we saw a Notably, we found that yearly PSA screening rates continued to decrease in younger men after the ACP and AUA recommendations in 2013 to use a shared decision-making approach to screening in men aged <70 years, declining even in men with known risk factors for prostate cancer. As discontinuing all prostate cancer screening may lead to an increase in avoidable cancer deaths [25] , strategies for riskbased screening are currently advocated [26] [27] [28] [29] [30] . In men aged 40-49 years, the screening rates were higher in those with risk factors for prostate cancer, including A-A men and in those with a family history of prostate cancer, suggesting that some individualised risk assessment or shared decisionmaking may occur with early screening in these men, but screening rates still continued to decrease. However, men with a family history of prostate cancer aged 50-69 years were screened at rates similar to men without a family history, and much lower than prior to the initial USPSTF recommendations in 2008.
Our present finding of lower rates of screening among A-A men compared to non-A-A men in the 50-69 years age group is concerning. A-A race is associated with greater biochemical failure after radical prostatectomy for low-grade prostate cancer [31] and also predicted adverse pathological features and pathological upgrading in men with very lowgrade prostate cancer who have radical prostatectomy [32] . Thus failure to diagnose even low-risk prostate cancer may adversely affect A-A men disproportionately and actually shortening PSA screening intervals may lessen the number of A-A men diagnosed with advanced disease [33] .
Regular access to a healthcare provider has been associated with PSA screening in A-A men [34, 35] . In our present study, we found that despite having significantly more visits per year with both PCPs and urology providers, A-A men still had lower rates of screening, possibly related to the variation in rates of offering of screening by providers or decreased acceptance of screening by A-A men, even with increased visits to a PCP.
On the other hand, men with a family history of prostate cancer did not have significantly more visits with a PCP than those without a family history, but were generally screened equally or more often, perhaps related to more visits with a urologist.
The median rates of provider ordering of PSA screening, as well as the 25th and 75th percentiles rates, decreased in general after the 2008 USPSTF recommendation. While it is not possible in the present study to determine the level of shared decision-making occurring around prostate cancer screening, the variation in provider ordering of PSA screening, with the minimal ordering rate of 0% in each study year, and maximum ordering rates that appear to be temporally unrelated to timing of guideline recommendations for screening, suggests that screening decisions may have been at least in part provider-driven throughout the study period.
Although total screening rates were lower, our present findings suggest that the providers who continue to screen patients may not be following a risk-based screening approach. The wide variation in provider ordering persisted even after adjustment for patient age and race (A-A vs non-A-A). Our present findings of decreased annual screening, as well as biennial and quadrennial re-screening rates, seem to be temporally related to the USPSTF recommendations against prostate cancer screening. We found similar rescreening rates in men with PSA levels of <1 and 1-3 ng/mL. PSA re-testing rates in men aged >75 years with a PSA level of <3 ng/mL were similar in the earlier and later cohorts, again suggesting that risk-based screening is not occurring. Overall our present findings suggest multiple factors other than PSA levels contributing to changing rates of PSA screening with evolving guidelines including age, risk factors (A-A race, family history of prostate cancer), and provider ordering patterns. The more recent recommendations for intervals of re-screening based upon previous PSA level do not appear to be being followed by PCPs, probably related to lack of awareness of these guidelines; if followed, these guidelines could substantially change practice.
Our present finding that rates of first prostate biopsy for men who were screened with a PSA test were higher in those men with known risks for prostate cancer in 2014 compared to 2007 suggests that possibly risk-based biopsy practices are being followed. Nonetheless, the PSA screening rates in all men, even those with risk factors for prostate cancer, decreased over the 2007-2014 period suggesting that the intervention truly needed at this time would be to encourage initial risk-based screening practices.
Limitations
Our present analysis represents prostate cancer screening patterns in PCPs in one health system and thus may not be generalisable to other geographic locations. In addition, our ability to capture family history of prostate cancer, or PSA tests ordered for non-screening purposes is dependent on provider documentation practices, which may have evolved over the study period. Our attribution of PCP associated with PSA testing to the provider with whom the patient had the greatest frequency of visits in the year of and year prior to the PSA test may not be the provider whom the patient considers to be their PCP. However, our decision was based on the assumption that the provider who had the most contact with the patient around the timing of the PSA test may have been the most influential in the patient's care. Finally, our present analyses could not control for patients who were seen by a urologist not in our healthcare system, and are limited to men who had a PSA test or prostate biopsy taken within our health system.
Conclusion
The rates of prostate cancer screening declined from 2007 to 2014, even in higher-risk groups, with large variation of PSA testing practices among PCPs, and without clear evidence for risk-based screening practices. However, rates of first prostate biopsy for men who were screened were higher in those men with known risks for prostate cancer in 2014 compared to 2007. Future work should further explore reasons the variation in prostate cancer screening, and encourage collaboration among primary care physicians and urologists, to implement shared decision-making and appropriate riskbased strategies for prostate cancer screening in primary care practices, especially in men with a family history of prostate cancer and in A-A men.
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